Skip Nav Destination
Issues
1 September 2006
-
Cover Image
Cover Image
X-linked inhibitor of apoptosis (XIAP) represents a novel therapeutic target for the induction of tumor apoptosis by a new investigational, second-generation antisense drug, AEG35156. Illustrated is the strong protein expression of XIAP within a non–small-cell lung cancer tumor xenograft, in the absence of AEG35156 treatment, using immunohistochemistry. AEG35156 treatment of tumor-bearing mice results in XIAP down-regulation and tumor regression when used as a single agent or in combination with chemotherapy. For further details, please see LaCasse et al. on page 5231 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Editorials
The Biology Behind
CCR Practice of Translational Oncology
Molecular Pathways
Review
Human Cancer Biology
Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting
John C. Sok; Francesca M. Coppelli; Sufi M. Thomas; Miriam N. Lango; Sichuan Xi; Jennifer L. Hunt; Maria L. Freilino; Michael W. Graner; Carol J. Wikstrand; Darell D. Bigner; William E. Gooding; Frank B. Furnari; Jennifer R. Grandis
Imaging, Diagnosis, Prognosis
Aurora Kinase A Messenger RNA Overexpression Is Correlated with Tumor Progression and Shortened Survival in Head and Neck Squamous Cell Carcinoma
Rudolf Reiter; Peter Gais; Uta Jütting; Miriam K. Steuer-Vogt; Anja Pickhard; Karin Bink; Sandra Rauser; Silke Lassmann; Heinz Höfler; Martin Werner; Axel Walch
Identification of Cripto-1 as a Novel Serologic Marker for Breast and Colon Cancer
Caterina Bianco; Luigi Strizzi; Mario Mancino; Aasia Rehman; Shin Hamada; Kazuhide Watanabe; Antonella De Luca; Brenda Jones; Gabriela Balogh; Jose Russo; Daniel Mailo; Raffaele Palaia; Giuseppe D'Aiuto; Gerardo Botti; Francesco Perrone; David S. Salomon; Nicola Normanno
Cancer Therapy: Clinical
Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies
Karen W.L. Yee; Zhihong Zeng; Marina Konopleva; Srdan Verstovsek; Farhad Ravandi; Alessandra Ferrajoli; Deborah Thomas; William Wierda; Efrosyni Apostolidou; Maher Albitar; Susan O'Brien; Michael Andreeff; Francis J. Giles
High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma
Rena Buckstein; Robert S. Kerbel; Yuval Shaked; Rakesh Nayar; Cindy Foden; Ruth Turner; Christine R. Lee; Diane Taylor; Liying Zhang; Shan Man; Sylvain Baruchel; Diana Stempak; Francesco Bertolini; Michael Crump
Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors
Alain C. Mita; Lisa A. Hammond; Peter L. Bonate; Geoffrey Weiss; Heather McCreery; Samira Syed; Mitchell Garrison; Quincy S.C. Chu; Johann S. DeBono; Christopher B. Jones; Steve Weitman; Eric K. Rowinsky
Cancer Therapy: Preclinical
Adenovirus-Mediated Calponin h1 Gene Therapy Directed against Peritoneal Dissemination of Ovarian Cancer: Bifunctional Therapeutic Effects on Peritoneal Cell Layer and Cancer Cells
Tomonori Ogura; Hiroaki Kobayashi; Yousuke Ueoka; Kaoru Okugawa; Kiyoko Kato; Toshio Hirakawa; Shigenari Hashimoto; Shun'ichiro Taniguchi; Norio Wake; Hitoo Nakano
Preclinical Characterization of AEG35156/GEM 640, a Second-Generation Antisense Oligonucleotide Targeting X-Linked Inhibitor of Apoptosis
Eric C. LaCasse; Gabriele G. Cherton-Horvat; Kimberley E. Hewitt; Lori J. Jerome; Stephen J. Morris; Ekambar R. Kandimalla; Dong Yu; Hui Wang; Wei Wang; Ruiwen Zhang; Sudhir Agrawal; John W. Gillard; Jon P. Durkin
Cancer Susceptibility and Prevention
Liver Intestine-Cadherin (CDH17) Haplotype Is Associated with Increased Risk of Hepatocellular Carcinoma
Xiao Qi Wang; John M. Luk; Mercè Garcia-Barcelo; Xiaoping Miao; Pauline P. Leung; David W. Ho; Siu Tim Cheung; Brian Y. Lam; Cindy K. Cheung; Ashley S. Wong; Silvana S. Lau; Man Ting So; Wan Ching Yu; Qi Cai; Karen S. Liu; Chee Kin Hui; George K. Lau; Ronnie T.P. Poon; John Wong; Sheung Tat Fan
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.